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Abstract 
Objective: Written emotional disclosure for 15-20 minutes a day over 3-4 days improves 
physical and psychological health, and may benefit cancer patients.  However, no studies 
have tested the effectiveness of guided writing in cancer patients and their partners. A 
randomized controlled trial tested whether writing about the patient’s diagnosis and treatment 
of ovarian cancer using the Guided Disclosure Protocol (GDP) is effective in reducing 
perceived stress and improving quality of life (QoL) in ovarian cancer couples. The study 
also tested two theories that may account for beneficial effects of written emotional 
disclosure, the cognitive processing hypothesis and the social interaction hypothesis.   
Methods:  Patients and their partners (N=102 couples) were randomised to write at home for 
15 minutes a day over three days about the patient’s diagnosis and treatment using the GDP 
or what the patient did the previous day (control). Couples were assessed at baseline, three 
and six month follow-ups on the primary outcomes of perceived stress and QoL, and 
secondary outcomes of intrusive thoughts (testing the cognitive processing hypothesis), and 
illness-related couple communication (testing the social interaction hypothesis).   
Results: There were no main effects for any outcomes.  However, in patients, the GDP 
improved QoL if illness-related couple communication improved, and buffered the effect of 
intrusive thoughts on perceived stress. 
Conclusions: The GDP might benefit patients in certain circumstances, through changes in 
communication (in line with the social interaction hypothesis).  Further research is needed to 
determine whether patients benefit from interventions to improve illness-related couple 
communication, and under which conditions. 
Keywords: written emotional disclosure, ovarian cancer, randomized controlled trial; 
partners  
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Ovarian cancer is the leading cause of death from gynaecological malignancies.  Five-
year survival in the UK is 41% [1].  It is often diagnosed at an advanced stage due to lack of 
or non-specific symptoms [2].  Consequently, despite aggressive treatment, most patients 
relapse within two years.  Patients often experience elevated levels of distress [3] and poor 
quality of life (QoL) [4-5], suggesting that psychological interventions should be well 
received.  However, in a systematic review of 18 interventions for patients with 
gynaecological cancers, only one reduced distress, and there were no effects on physical 
symptoms or functioning [6]. Furthermore, due to multiple methodological limitations 
including small sample sizes, low consent rates, floor effects and high loss to follow-up, 
generalizability of these studies to the clinic is questionable.  Finally, such interventions are 
costly and time-consuming. 
An inexpensive, adjunct alternative may be written emotional disclosure of traumatic 
events for as little as 15 minutes a day over three days, which has led to improved mental and 
physical health across 146 studies [7], and physical health in clinical populations [8]. 
Fourteen studies have tested written disclosure in cancer patients [9-22]. Although some 
small, possibly underpowered studies [9-11, 14, 16] demonstrated negative findings, 
improvements have been demonstrated in physical symptoms [12, 18, 22], psychological 
distress [18], and QoL [22] in breast cancer, particularly when participants are required 
to write about their cancer [12, 18, 22].  One large study with negative findings [20] 
demonstrated reductions in depressive symptoms in women who wrote about their 
cancer.  Written disclosure has also improved couple-related outcomes in other populations 
[23-25].  By inducing self-reflection, couple-related writing may act as a springboard for 
discussing the illness, and thus reduce distress and improve QoL in both partners. 
Several theories may explain the effectiveness of written disclosure. The cognitive 
processing hypothesis holds that written disclosure may enable coherent restructuring of 
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traumatic memories into existing schemas [26-27], leading to resolution of the trauma and 
improved physical health [28].   Based on this theory, improved mood following writing 
should be mediated through reductions in intrusive thoughts, reflecting more cognitive 
control over traumatic information. Also, structured writing should facilitate cognitive 
restructuring of traumatic memories. Duncan and Gidron [29] therefore developed the Guided 
Disclosure Protocol (GDP).  In addition to describing their thoughts and feelings at the time 
of the event (Day 2), participants describe the event chronologically, with causal links 
between the event’s segments (Day 1), reflect on how the event affected their life (Day 2) and 
write how they currently think and feel about the event, and reflect on future coping with a 
similar event (Day 3) (see [29-30]). The GDP has reduced visits to general practitioners in 
frequent attendees [30], and reduced PTSD symptoms in parents of children with cancer [31].  
Also, similar structured writing has reduced disease activity in rheumatoid arthritis [32] and 
improved psychological wellbeing in fibromyalgia [33].  However, the GDP has not been 
tested in cancer. 
The social interaction hypothesis [34] holds that people may be able to interact with 
others more positively following written disclosure, due to reduced distress and greater self-
control.  Subsequent increased social sharing following written disclosure (see [35-36]) alerts 
others to the person’s psychological state, and may increase social support and problem-
solving, leading to improved psychological well-being   
This study tested the effectiveness of writing about the patient’s diagnosis and treatment 
for 15 minutes a day over 3 days, using the GDP, on reducing perceived stress and 
improving QoL in ovarian cancer couples, relative to writing about what the patient did the 
previous day.  GDP participants were expected to demonstrate significantly greater 
improvements in QoL and reductions in perceived stress three months post intervention, 
maintained at six months.  A secondary aim was to test whether improvements were mediated 
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through reductions in intrusive thoughts, based on the cognitive processing hypothesis, or via 
improved illness-related couple communication, based on the social interaction hypothesis.   
Method 
The GDP [25] for written emotional disclosure was compared to control writing in a 
randomized controlled trial (RCT).  The study was approved by the relevant departmental 
ethics committee.  It followed CONSORT guidelines for designing and reporting RCTs [37]. 
 
Participants 
 Participants were members of a UK charity for patients with ovarian cancer who had 
consented to be contacted by third parties, and their spouses/partners.  Invitation letters were 
sent out to 530 patients with the title ‘Mrs’ (to maximize recruitment of couples), at four time 
points over 13 months.  Interested individuals returned their details in a stamped addressed 
envelope, and were screened by telephone to determine eligibility and stratify accurately.  
Uninterested individuals were requested to fill in a slip indicating why from ‘I am not 
interested’, ‘I am too busy,’ ‘I am not feeling well’ or ‘Other’.  Eligible participants had been 
diagnosed with ovarian cancer, were no more than five years post-treatment, able to read and 
write in English, and age 18 years or above. Spouses lived with a partner with ovarian cancer. 
Of 336 respondents who returned a slip or contacted the researcher indicating receipt 
of the letter1, 203 (60%) expressed interest in the study, and 141 couples were eligible.  The 
other 133 were not interested (felt too ill, too busy, or thought the study was not relevant, 
often due to length of time since their last treatment). Reasons for ineligibility included being 
single (n=28), and more than five years since their last treatment (n=34).  Of these 141 
couples, 102 completed baseline measures and were randomized. 
 
                                                 
1The Ovacome database is not based on hospital records, but updated by members and their families.  Many of 
those who did not respond to the initial letter may have been in hospital, died, moved away or been ineligible to 
participate. 
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Procedure 
As participants lived all over the UK, assessments and experimental procedures were 
carried out by mail and telephone, and the writing completed at home.  Eligible participants 
were sent the initial questionnaire (including all measures described below) and a consent 
form.  Following consent, the writing booklet was sent out, and the writing scheduled for 
three days within the same week (ideally consecutive).  Patients and their partners could 
choose to write at the same time or different times. 
Each day, the participant was telephoned at a designated time, and asked to go to a 
quiet place, and write continuously for 15 minutes, after which the researcher telephoned 
again, to tell them to stop.  After the last session, participants returned the writing by post, to 
be typed up and content analyzed.  At three and six months, follow-up questionnaires were 
mailed out.  Mail was returned to a researcher who had no contact with the participants.  
Recruitment took place over 13 months. Flow of participants through the trial and follow-up 
rates at each time point are reported in Figure 1. 
 
Design 
In an RCT, couples were randomly assigned to written emotional disclosure about the 
patient’s diagnosis and treatment (GDP; n=53) or writing about what the patient did the 
previous day, (control; n=49), for 15 minutes a day over three days.  This controlled for 
experimenter contact (participants were telephoned before and after writing), and the partner 
thinking about the patient (partners wrote about the patient’s activities) [33]. Randomization 
was conducted before study commencement, in blocks of 10, using www.randomization.com, 
matching for recurrence since initial diagnosis, to increase the probability of obtaining 
equivalent groups regarding prognosis.  Opaque envelopes were numbered and the 
appropriate condition written inside each envelope according to the randomization table, 
which was then destroyed. The envelopes were locked in a cabinet and inaccessible to anyone 
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involved in the project.  Each participant was allocated a number based on the order in which 
they entered the trial, which corresponded with a numbered envelope.  An independent 
administrator opened the cabinet and appropriate envelope, and informed the first author of 
group assignment, after which the appropriate task was posted out. 
As a single researcher carried out this study, double blinding was not possible. To 
reduce risk of measurement bias, questionnaires were returned to a researcher who had no 
contact with the participants and was unaware of group allocation.  Also, all outcomes were 
assessed by self-report questionnaires, which participants filled in at home. To reduce risk of 
performance variability, the writing instructions were stated clearly on the booklet, and the 
writing tasks timed.  Participants were informed that writing had improved health across a 
variety of illnesses, and they would be asked to write about events in either an emotional or a 
non-emotional way, to ensure expectations did not differ by group. 
 
Written emotional disclosure  
The GDP protocol was as follows:   
Day 1: Describe the diagnosis and treatment chronologically, and what led to what, without 
mentioning emotions.   
Day 2: Part 1: Describe how you felt and what you thought at the time of the diagnosis; Part 
2:  What impact has your diagnosis and treatment had on your life, and has it caused you to 
change priorities?  
Day 3: How do you currently feel and think about the diagnosis and treatment.  Are your 
current thoughts and feelings the same as at diagnosis?  Would you be able to cope with 
similar situations better because you have experienced it.   
Spouses received similar instructions regarding their partner’s cancer and their own 
responses/reflections.   
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Neutral writing  
Both members of the couple wrote about what the patient did the previous day. 
 
Measures 
Demographic and medical information 
This included age, occupation, educational level, marital status and time married.  For 
patients, medical information about disease stage, time since diagnosis, time since last 
treatment, treatment (surgery, chemotherapy and radiotherapy), number of courses of 
chemotherapy, whether currently undergoing treatment (question repeated at each follow-up), 
and CA 125 level (a tumour marker with high prognostic value in ovarian cancer) were self-
reported.  Thirty one of the CA 125 results were later checked with the patients’ oncologists, 
with patient consent (correlation r=.99). CA 125 scores were then categorized as above or 
below 35 U/ml [38], and inter-rater reliability was Kappa=.995 (p <.0.001).   
 
 
Primary Outcomes 
Quality of Life (QoL) 
The Functional Assessment of Cancer Therapy- General (FACT-G; [39]) assesses 
QoL in patients with cancer.  Patients completed the physical (7 items), social/family (6 
items), and functional wellbeing (7 items) subscales2. Cronbach’s Alpha ranged from .88 
to .91, indicating good reliability.  Partners completed the physical (6 items), social/family (5 
items), and functional wellbeing (6 items) subscales of the FACT-GP [40], an equivalent 
scale for assessing QoL in the general population. Cronbach’s alpha ranged from .81 to .84. 
In both scales, higher scores indicate better QoL.  
Perceived Stress 
The Perceived Stress Scale (PSS; [41]) is a 10-item scale measuring the extent to 
which individuals perceived they were unable to cope with stress during the past month.  
                                                 
2 The emotional well-being subscale had low reliability in a pilot study, hence was not utilized. 
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Higher scores indicate higher levels of perceived stress. Cronbach’s alpha ranged from .90 
to .91 for patients, and from .87 to .89 for partners, indicating excellent reliability. 
Secondary Outcomes 
Intrusive thoughts 
The intrusions subscale (8 items, higher scores indicate higher levels of intrusive 
thoughts) of the Impact of Event Scale-Revised (IES-R; [42]) assesses intensity of intrusive 
thoughts ‘during the past seven days’. It was completed with regard to the patient’s cancer. 
Cronbach’s alpha ranged from .91 to .92 for patients, and from .90 to .92 for partners, 
indicating excellent reliability. 
Couple communication 
The Couples’ Illness Communication Scale (CICS) is a 4 item scale assessing illness-
related couple communication [43].  Higher scores indicate better communication.  Items 
cover the individual’s ability to discuss the illness with their partner and their impression of 
their partner’s willingness to discuss the illness with them.  Cronbach’s alpha ranged from .80 
to .85 for patients, and from .72 to .80 for partners, indicating good reliability.   
 
Word counts and Manipulation Checks  
Percentages of positive emotion, negative emotion, and insight (e.g., understood, 
realised) words were computed for each writing day, using the programme Linguistic Inquiry 
and Word Count (LIWC; [44]).  Also, after each writing session, participants rated how 
personal and revealing of emotions they felt their essays were (Pennebaker, 1994, 
unpublished manuscript).   
 
Sample size calculation 
This was based on the results for the PSS (one of the primary outcomes) from an 
unpublished pilot study on written emotional disclosure and telephone-based stress 
management in 27 women with ovarian cancer.  A calculation based on the difference 
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between the means at first baseline and one month following written disclosure revealed an 
effect size of 0.70.  With 80% power and p < .05 statistical significance, using two-tailed 
tests, 32 participants per group were required to obtain statistical significance.  However, as it 
included two primary outcomes and a longer follow-up period, we aimed to recruit 50 
participants per group.  
 
Statistical analysis  
To determine equivalence between groups on demographic and biomedical 
characteristics, independent samples T-tests were used for continuous data, and chi-square 
analysis for categorical data. To test the research questions, 2 x 3 mixed-design repeated 
measures analyses of covariances (ANCOVA) were performed, with group (GDP, control) as 
the between-subjects factor, and time (baseline, 3 and 6 months follow-up) as the within-
subjects factor. The main test was a time x group interaction, followed by tests to determine 
the source of any observed interaction. Effect sizes (Cohen’s d) were calculated from η2. 
Analyses controlled for baseline demographic and illness differences between groups and 
were intention-to-treat, by carrying the last observation forward [45].  
 
Results 
Baseline demographic and disease-related characteristics of patients and partners by 
group are reported in Table 1. GDP participants were significantly younger than controls, and 
more time had passed since their diagnosis.  Therefore, patient age and time since diagnosis 
were added as covariates.  Also, having treatment at retest was included as a covariate, to 
partly rule out effects of disease progression and new treatments on outcomes.  
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Manipulation checks 
GDP participants used more positive and negative emotion and insight words on days 
2 and 3 than controls.  They also rated their essays as more personal and revealing of 
emotions across all three days (all p values <.01).   
 
Primary Outcomes: Effects of Written Emotional Disclosure on Perceived Stress and Quality 
of Life (QoL) 
The general linear models showed that for perceived stress, there was no group by 
time interaction for patients (F (2, 168) = .30, p=.74; Cohen’s d = 0.11) or partners (F (2, 
168) = 2.18, p=.12; Cohen’s d = 0.35).  Similarly, for QoL, there was no group by time 
interaction for patients (F (2, 168) = 2.56, p=.08; Cohen’s d = 0.35) or partners (F (1.75, 
145.45) = 1.30, p = .28; Cohen’s d = 0.29). The descriptive data are presented in Table 2. 
 
Secondary Outcomes: Cognitive processing hypothesis and social interaction hypothesis 
There was no group by time interaction for intrusive thoughts in patients (F (2, 168) = 
0.46, p=.63; Cohen’s d = 0.14), but a significant interaction for partners (F (2, 168) = 3.76, 
p=.03; Cohen’s d = 0.4).  Planned contrasts revealed the change occurred between baseline 
and three months (F (1, 83) = 6.87, p=.01) but not between three and six months (F (1, 78) = 
0.007, p=.94).  The effect was linear, indicating this was due to an increase in intrusive 
thoughts from baseline to three months in the GDP group only.  There was no group by time 
interaction for illness-related couple communication in patients (F (1.72, 144.53) = .77, 
p=.45; Cohen’s d = 0.19) or partners (F (2, 168) = 2.44, p=.09; Cohen’s d = 0.35).   
 
Mediators and Moderators 
As there was no effect of the GDP on the primary outcomes, no tests for mediators 
were carried out.  Nevertheless, the intervention was hypothesised to have benefited 
participants who improved on the secondary outcomes (intrusive thoughts and illness-related 
communication).  To test this, change in intrusive thoughts and change in illness-related 
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communication were hypothesised to be moderated mediators (moderator variables whose 
values influence the process by which treatment leads to the outcome: [46]) of the relation 
between group and the primary outcomes.  These change scores were centred to reduce 
multicollinearity. Analyses covered only the period from baseline to three months, when most 
change was expected to take place, to reduce chance of type-I errors. 
As both hypothesized moderated mediators were continuous variables, hierarchical 
multiple linear regressions were utilised.  The primary outcome at three months (i.e., QoL) 
was entered as the DV.  The primary outcome at baseline was entered as a predictor on the 
first step, followed by group, the z-score of the moderated mediator and the interaction term 
of group by the z-score of the moderated mediator on the second step.   
Change in illness-related communication moderated the effect of group on QoL in 
patients.  The interaction explained 2.3% of the variance in QoL at three month follow-up: (B 
= 1.17, SE = .52, β = .20; F (1, 85) = 5.16, p=.03).  Plotting QoL against change in illness-
related communication for each group following [47] (see Figure 2) showed that for the 
control group, QoL was high regardless of change in illness-related communication, whereas 
for the GDP group, QoL was better if illness-related communication improved, and worse if 
it worsened.  Change in intrusive thoughts moderated the effect of group on perceived stress 
in patients.  This interaction explained 3% of the variance in perceived stress at three month 
follow-up (B = -.43, SE = .16, β = -2.66; F (1, 84) = 7.07, p=.009).  Plotting perceived stress 
against change in intrusive thoughts for each group (see Figure 3) showed that for the control 
group, an increase in intrusive thoughts was associated with more perceived stress at three 
months, whereas for the GDP group, change in intrusive thoughts did not influence perceived 
stress. No moderated mediators were identified for partners. 
 
 
 
13 
 
Discussion 
This study aimed to determine the effect of the GDP on perceived stress and QoL in 
ovarian cancer couples.  However, contrary to expectations, despite including partners, there 
was no effect of the GDP on the primary outcomes. Approximately half the participants 
experienced a recurrence during the study.  Written disclosure may be ineffective for dealing 
with recurrent stressors, as it does not teach strategies for dealing with possible recurrences.  
Studies with positive effects of writing on outcomes [12, 18, 22] have been carried out in 
patients with breast cancer, which has a much better prognosis than ovarian cancer, and have 
used standard non-guided writing, which may account for the differences in outcome.   
Similarly, the cognitive processing hypothesis was not supported.  Intrusive thoughts 
even increased in partners in the GDP group.  Many patients may have already come to terms 
with the event (few reported high levels of intrusive thoughts).  Alternatively, reductions in 
intrusive thoughts after writing have not been demonstrated in patients with chronic illness 
[8], which may be considered a concurrent stressor.  Although it can be methodologically 
difficult to capture changes in cognitive processing, this finding means the GDP cannot be 
recommended for partners of patients with cancer.   
Similarly, the social interaction hypothesis was not supported.  There was no effect of 
the GDP on communication.  Distressed couples are less likely to agree to participate in such 
studies [48], and CICS scores at baseline were high, suggesting communication was close to 
ceiling level.  The GDP may be more effective in improving communication in couples 
experiencing communication problems.  Alternatively, for illness-related communication to 
improve, couples may require training in communication skills.   
In patients, enhanced illness-related communication was associated with better QoL 
in the GDP group only.  Writing about emotional aspects of the cancer may have led some 
couples to share feelings and thoughts not previously revealed, leading to improved illness-
related communication and coping with the disease, and thus improved QoL.  This 
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relationship fits in with the moderated mediation model outlined by Preacher where a fourth 
variable affects the path between the independent variable and the moderator [49] (see Figure 
4).  Writing prior to discussing the illness may help break down social constraints, organize 
thoughts and enhance disclosure [13, 31].  Conversely, writing and not talking may resurface 
issues that are not addressed, leading to increased social constraint.  To test this hypothesis, 
direct assessment of communication by asking participants about how much they discussed 
the illness with their partner after writing is required. 
In patients, the GDP buffered the effect of increased intrusive thoughts.  An increase 
in intrusive thoughts was not associated with increased perceived stress at three months, in 
the GDP group only.  The GDP may have enhanced self-efficacy for dealing with distressing 
cancer-related thoughts, by enabling reflection on coping with the illness.  Precise verbal 
labelling of unpleasant emotions and causally linking aspects of their memories in the GDP 
may enable individuals to process such contents in more controlled prefrontal regions, and 
regulate unpleasant intrusions possibly emanating from limbic-level processing [50].  
Further research is needed to test whether the GDP is effective in preventing distress in 
individuals experiencing high levels of intrusive thoughts. 
Several issues need to be addressed in future research.  Fifteen minutes was often 
insufficient for participants to describe their diagnosis and treatment.  On Day 1, participants 
should be invited to write until they feel they have completed all necessary details or be 
provided with e.g., 30 minutes.  Also, the results were based on a cancer that affects only 
women.  The effects of structured writing about cancer/other chronic illnesses where the man 
is the patient need to be determined.   
This study had several limitations.  First, for ethical reasons, no demographic 
information was collected about non-responders, preventing comparisons with responders.  
Second, the power analysis was based on an anticipated large effect size.  Basing it on 
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effects of written disclosure in cancer from previous studies (with smaller effects) might 
have been more appropriate.  Third, medical data was self-reported.  Although the high 
correlation between patient- and consultant-reported CA 125 levels suggested it was accurate, 
medical information would ideally have been validated against records.  Fourth, the 
participants were members of a support charity, thus possibly more motivated to engage in 
the study than the general population with ovarian cancer due to use of more active coping 
strategies [51]. Finally, the PSS may not have captured cancer-related distress 
sufficiently.  The full IES might have been a more appropriate measure of cancer-
related distress.  Avoidant coping as measured by the IES avoidance subscale could also 
have mediated the results.  
Overall, the findings suggest guided written emotional disclosure is not effective for 
all ovarian cancer couples, and may even cause negative effects in partners.  However, in 
patients, change in illness-related communication moderated improvements in QoL, 
suggesting that further research is required to determine whether the GDP benefits 
patients if the instructions promote communication. Testing whether the GDP reduces 
intrusive thoughts in individuals high in perceived stress is also recommended.  If these 
protective effects can be replicated, it is important to understand the mechanisms by 
which they may occur and whom the GDP may benefit. 
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Table 1: Baseline demographic and illness characteristics of patients and partners 
 GDP 
(n=53) 
Control (n=49) Statistical 
comparison 
Patients’ Age (Mean, SD) 53.02 (10.30) 57.39 (8.09) t = 2.32 (p=.02)* 
Disease stage:    
I 12 (22.6%) 11 (22.4%) χ2 = 3.89 (p=.27) 
II 4 (7.55%) 10 (20.4%)  
III 30 (56.6%) 24 (49.0%)  
IV 7 (13.2%) 4 (8.16%)  
Months since diagnosis (Mean, SD) 43.29 (34.05) 31.54 (21.22) t = -2.09 (p=.04)* 
Months since treatment (Mean, SD) 16.40 (19.44) 13.65 (15.34) t = -.78 (p=.44) 
Having treatment 7 (13.2%) 6 (12.2%) χ2 = .02 (p=1) 
Had recurrence 30 (56.6%) 24 (49.0%) χ2 = .59 (p=.55) 
Number of chemotherapy courses 
(Mean, SD) 
1.85 (1.35) 1.53 (0.96) t = -1.36 (p=.18) 
Had surgery 51 (96.2%) 43 (87.8%) χ2 = 2.52 (p=.15) 
Had radiotherapy 6 (11.3%) 5 (10.2%) χ2 = .03 (p=1) 
Years married/ living with partner 
(Mean, SD) 
25.67 (13.66) 28.62 (10.98) t = 1.11 (p=.27) 
Education:   χ2 = 1.92 (p=.38) 
GCSEs 16 (30.2%) 21 (42.9%)  
A-levels/ equivalent 18 (34.0%) 15 (30.6%)  
Degree 19 (35.8%) 13 (26.5%)  
Employed 23 (43.4%) 14 (28.6%) χ2 =2.42 (p=.15) 
Partners’ age (Mean, SD) 55.34 (10.92) 60.43 (9.22) t = 2.33 (p=.02) 
Partners’  education:   χ2 = .15 (p=.93) 
GCSEs 14 (26.4%) 11 (22.4%)  
A-levels/ equivalent 18 (34.0%) 16 (32.7%)  
Degree 21 (39.6%) 22 (44.9%)  
Partner employed 
 
 
24 (45.2%) 35 (71.4%) χ2 = 3.04 (p=.11) 
CA 125 level (Mean, SD) 60.43 (165.64) 65.64 (105.25) t = .21 (p=.83) 
*p<.05 
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Table 2: Scores for the primary and secondary outcomes by group: patients and partners 
(means presented with standard deviations in brackets) 
Outcome  Group Baseline 3 month 
follow-up 
6 month follow-
up 
Quality of Life Patients GDP 58.87 (12.53) 56.00 (15.30) 56.30 (14.96) 
  Control 60.13 (11.06) 60.26 (11.77) 60.26 (12.58) 
 Partners GDP 45.75 (7.40) 46.86 (7.61) 45.50 (7.63) 
  Control 50.94 (8.99) 49.57 (8.53) 49.11 (8.90) 
Perceived Stress Patients GDP 18.10 (7.70) 18.95 (7.68) 18.85 (7.74) 
  Control 14.17 (7.67) 15.09 (6.92) 16.23 (7.82) 
 Partners GDP 15.13 (6.69) 17.13 (6.52) 16.45 (6.19) 
  Control 12.29 (6.92) 12.40 (6.36) 13.29 (7.68) 
Intrusive 
thoughts 
Patients GDP 10.90 (7.46) 10.68 (8.00) 11.40 (7.59) 
  Control 8.92 (6.96) 9.06 (6.55) 9.36 (6.90) 
 Partners GDP 8.14 (5.95) 9.95 (7.49) 10.24 (6.92) 
  Control 8.54 (6.59) 7.86 (6.28) 8.03 (6.21) 
Illness-related 
couple 
communication 
Patients GDP 13.63 (4.10) 14.00 (3.72) 14.10 (3.62) 
  Control 13.58 (3.65) 14.39 (3.27) 14.28 (3.34) 
 Partners GDP 14.65 (3.58) 14.30 (3.79) 14.38 (3.45) 
  Control 16.20 (2.71) 14.86 (3.43) 15.26 (3.27) 
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Figure 1: Flow of participants through the trial  
 
Assessed for eligibility (203) 
Excluded (n= 62) 
• Not meeting inclusion criteria 
(62) 
• Patient refused to participate (0) 
•  
Questionnaires returned (n=41) 
Lost to follow-up (n= 3) 
• Patient died (2) 
• Partner dropped out (1) 
 
 
GDP (n= 53) 
Couple received intervention (n=44) 
Patient did not complete intervention (n=2) 
• Too ill (1) 
• Not interested (1) 
Partner did not receive intervention (n=7) 
• Not interested (7) 
 
 
 Questionnaires returned (n=39) 
Lost to follow-up (n= 5) 
• Patient died (3) 
• Partner failed to return 
questionnaire (1) 
• Couple dropped out (1) 
• Couple withdrew (1) 
  
Control (n= 49) 
Couple received intervention (n= 44) 
Patient did not complete intervention (n=2) 
• Not interested (1) 
• Died (1) 
Partner did not receive intervention (n=3) 
• Not interested (3) 
Analyzed (intention-to-treat) (n=49) 
 
 
 
 
 
Allocation 
Analysis 
3 month follow-up 
questionnaire 
  
Enrolment 
Randomized 
Returned initial questionnaire (102) 
• Couple not interested (12) 
• Partner ill/ not interested (21) 
• Woman died: (2) 
• Woman too ill (4) 
 
6 month follow-up 
questionnaire 
  
Questionnaires returned (n=39) 
Lost to follow-up (n= 2) 
• Patient too ill (1) 
• Questionnaire not returned (1) 
Questionnaires returned (n=37) 
Lost to follow-up (n=2) 
• Patient died (1)    
• Questionnaire not returned (1) 
Replied to invitation (336) 
Analyzed (intention-to-treat) (n=53) 
 
Invitation sent out (530) 
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Figure 2: Change in illness-related communication as a moderator of the effects of group on 
quality of life – patients 
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Figure 3: Change in intrusive thoughts as a moderator of the effects of group on perceived 
stress – patients 
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